GFAP, along with ubiquitin C-terminal hydrolase 1 (UCH-L1), was the first biomarker for concussion to be approved by the United States Food and Drug Administration (FDA) in 2018 [3] using an enzyme-linked immunosorbent assay (ELISA)-based method by Banyan Biomarkers Inc. to predict intracranial injuries on computed tomography (CT) head scan with 97.6% sensitivity. This evidence concerns the gene GFAP and brain injury.